Literature DB >> 10457335

Cholecystokinin-A receptor messenger RNA expression in human pancreatic cancer.

R Moonka1, W Zhou, R H Bell.   

Abstract

Cholecystokinin (CCK) is a gut peptide hormone known to stimulate postprandial gallbladder contraction and pancreatic enzyme secretion. It has also been shown to induce the growth of normal pancreas and of malignant and premalignant lesions in rodents. Although CCK has been shown to promote the growth of human adenocarcinoma cell lines, its role in the growth of human pancreatic adenocarcinomas in vivo is less clear. Localization of CCK receptors to neoplastic cells within resected human tissue specimens would be suggestive of its potential action as an in vivo promoter of human pancreatic cancer. Resected tissue specimens of pancreatic adenocarcinomas were therefore studied by both reverse transcriptase-polymerase chain reaction (RT-PCR) and in situ hybridization for the presence of CCK-A receptors. Ninety percent of studied tumors demonstrated CCK-A expression by RT-PCR, and this expression was localized to neoplastic cells by in situ hybridization. An increase in the expression of CCK receptors is a mechanism by which pancreatic malignancies may gain a significant growth stimulus.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10457335     DOI: 10.1016/s1091-255x(99)80022-5

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.267


  28 in total

1.  Cholecystokinin-A and cholecystokinin-B/gastrin receptor mRNA expression in the gastrointestinal tract and pancreas of the rat and man. A polymerase chain reaction study.

Authors:  H J Monstein; A G Nylander; A Salehi; D Chen; I Lundquist; R Håkanson
Journal:  Scand J Gastroenterol       Date:  1996-04       Impact factor: 2.423

2.  Response to exogenous cholecystokinin of six human gastrointestinal cancers xenografted in nude mice.

Authors:  C Hudd; M C LaRegina; J E Devine; D C Palmer; D R Herbold; M C Beinfeld; F B Gelder; F E Johnson
Journal:  Am J Surg       Date:  1989-04       Impact factor: 2.565

3.  Establishment of a new human pancreatic adenocarcinoma cell line, MDAPanc-3.

Authors:  M L Frazier; S Pathak; Z W Wang; K Cleary; S E Singletary; M Olive; B Mackay; P A Steck; B Levin
Journal:  Pancreas       Date:  1990       Impact factor: 3.327

4.  Inhibition of cholecystokinin-stimulated pancreaticobiliary output in man by the cholecystokinin receptor antagonist MK-329.

Authors:  P Cantor; O Olsen; B J Gertz; I Gjorup; H Worning
Journal:  Scand J Gastroenterol       Date:  1991-06       Impact factor: 2.423

5.  Localization of cholecystokinin A and cholecystokinin B-gastrin receptors in the human stomach.

Authors:  J C Reubi; B Waser; U Läderach; C Stettler; H Friess; F Halter; A Schmassmann
Journal:  Gastroenterology       Date:  1997-04       Impact factor: 22.682

6.  Vagal afferent pathway mediates physiological action of cholecystokinin on pancreatic enzyme secretion.

Authors:  Y Li; C Owyang
Journal:  J Clin Invest       Date:  1993-07       Impact factor: 14.808

7.  Trophic effects of unsulfated cholecystokinin on mouse pancreas and human pancreatic cancer.

Authors:  E B Heald; S T Kramer; J P Smith
Journal:  Pancreas       Date:  1992       Impact factor: 3.327

8.  Correlation of cholecystokinin receptors with gallbladder contractility in patients with gallstones.

Authors:  J R Upp; W H Nealon; P Singh; C J Fagan; A S Jonas; G H Greeley; J C Thompson
Journal:  Ann Surg       Date:  1987-06       Impact factor: 12.969

9.  Stimulation of growth of azaserine-induced putative preneoplastic lesions in rat pancreas is mediated specifically by way of cholecystokinin-A receptors.

Authors:  S P Povoski; W Zhou; D S Longnecker; B D Roebuck; R H Bell
Journal:  Cancer Res       Date:  1993-09-01       Impact factor: 12.701

10.  Loxiglumide (CR1505), a cholecystokinin antagonist, specifically inhibits the growth of human pancreatic cancer lines xenografted into nude mice.

Authors:  Y Nio; M Tsubono; H Morimoto; K Kawabata; Y Masai; H Hayashi; T Manabe; M Imamura; M Fukumoto
Journal:  Cancer       Date:  1993-12-15       Impact factor: 6.860

View more
  7 in total

1.  Effects of lorglumide on growth and invasion of human pancreatic cancer cell line Mia PaCa-2 in vitro through the cholecystokinin-cholecystokinin-1 receptor pathway.

Authors:  Jin Zhou; Zi-Xiang Zhang; De-Chun Li
Journal:  Curr Ther Res Clin Exp       Date:  2010-08

2.  CCK1 receptor is involved in the regulation of protein lysine acetylation in GBC-SD cells and gallbladder carcinoma.

Authors:  W Wu; B Ouyang; Z Lu; H Liu; Y Tan; P Cui
Journal:  Ir J Med Sci       Date:  2017-05-03       Impact factor: 1.568

Review 3.  The production and role of gastrin-17 and gastrin-17-gly in gastrointestinal cancers.

Authors:  Jeffrey Copps; Richard F Murphy; Sándor Lovas
Journal:  Protein Pept Lett       Date:  2009       Impact factor: 1.890

4.  Expression of cholecystokinin receptors in colon cancer and the clinical correlation in Taiwan.

Authors:  Bee-Piao Huang; Chun-Hsiang Lin; Yi-Ching Chen; Shao-Hsuan Kao
Journal:  Tumour Biol       Date:  2015-10-27

5.  Expression of multiple forms of 3'-end variant CCK2 receptor mRNAs in human pancreatic adenocarcinomas.

Authors:  Anna Ryberg; Kurt Borch; Hans-Jürg Monstein
Journal:  BMC Res Notes       Date:  2011-04-19

6.  Differential expression of cholecystokinin A receptor in gallbladder cancer in the young and elderly suggests two subsets of the same disease?

Authors:  Hasan Raza Kazmi; Abhijit Chandra; Kavita Baghel; Anshuman Singh; Jaya Nigam; Devendra Parmar; Abbas Ali Mahdi; Sudhir K Goel; Sandeep Kumar
Journal:  Biomed Res Int       Date:  2014-06-15       Impact factor: 3.411

Review 7.  Gastrin, Cholecystokinin, Signaling, and Biological Activities in Cellular Processes.

Authors:  Qiang Zeng; Lei Ou; Wei Wang; Dong-Yu Guo
Journal:  Front Endocrinol (Lausanne)       Date:  2020-03-06       Impact factor: 5.555

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.